Sensus Healthcare (NASDAQ:SRTS) Stock Price Crosses Above 50-Day Moving Average – Should You Sell?

Sensus Healthcare, Inc. (NASDAQ:SRTS) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.92 and traded as high as $2.98. Sensus Healthcare shares last traded at $2.98, with a volume of 10,982 shares changing hands.

Analyst Ratings Changes

A number of research analysts recently weighed in on SRTS shares. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th. Finally, Wall Street Zen cut Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.88.

Sensus Healthcare Trading Up 1.4%

The firm has a market capitalization of $49.05 million, a P/E ratio of -6.34 and a beta of 1.10. The business’s 50 day simple moving average is $2.92 and its two-hundred day simple moving average is $3.72.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The business had revenue of $3.39 million during the quarter, compared to the consensus estimate of $5.32 million.

Institutional Trading of Sensus Healthcare

A number of institutional investors have recently made changes to their positions in SRTS. Geode Capital Management LLC grew its stake in shares of Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after acquiring an additional 3,766 shares during the period. Sachetta LLC boosted its holdings in Sensus Healthcare by 6.8% in the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after purchasing an additional 9,500 shares during the last quarter. Pacific Ridge Capital Partners LLC grew its position in Sensus Healthcare by 21.8% in the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after purchasing an additional 125,245 shares during the period. Jane Street Group LLC purchased a new stake in Sensus Healthcare during the 4th quarter valued at $79,000. Finally, State Street Corp lifted its holdings in shares of Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after buying an additional 3,400 shares during the period. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.